Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2023 Earnings Guidance

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) updated its FY 2023 earnings guidance on Tuesday. The company provided EPS guidance of $4.85-$5.00 for the period, compared to the consensus EPS estimate of $4.63. The company issued revenue guidance of $124.00 million-$128.00 million, compared to the consensus revenue estimate of $131.17 million. Ligand Pharmaceuticals also updated […]

Related Keywords

Stephenl Sabba ,Johnw Kozarich , ,News Ratings For Ligand Pharmaceuticals Daily ,Ligand Pharmaceuticals ,Advisor Group Holdings Inc ,Barclays ,Securities Exchange Commission ,Financial Services Group Inc ,Ligand Pharmaceuticals Stock ,Institutional Investors Weigh In On Ligand Pharmaceuticals ,Ligand Pharmaceuticals Incorporated ,Get Free Report ,Director John ,Exchange Commission ,Director Stephen ,Services Group ,Advisor Group Holdings ,Group Holdings ,Pharmaceuticals Incorporated ,Ligand Pharmaceuticals Daily ,Nasdaq Lgnd ,Lgnd ,Medical ,53220k50 ,Guidance ,Earnings ,Preannouncement ,